X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs AJANTA PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA AJANTA PHARMA DISHMAN PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 25.1 20.1 124.6% View Chart
P/BV x 3.3 8.7 38.4% View Chart
Dividend Yield % 0.7 0.7 96.4%  

Financials

 DISHMAN PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
AJANTA PHARMA
Mar-16
DISHMAN PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,720 21.8%   
Low Rs1291,103 11.7%   
Sales per share (Unadj.) Rs197.8194.6 101.6%  
Earnings per share (Unadj.) Rs21.245.2 46.9%  
Cash flow per share (Unadj.) Rs34.750.3 69.0%  
Dividends per share (Unadj.) Rs2.008.00 25.0%  
Dividend yield (eoy) %0.80.6 140.2%  
Book value per share (Unadj.) Rs179.9132.0 136.2%  
Shares outstanding (eoy) m80.6988.77 90.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.37.3 17.5%   
Avg P/E ratio x11.931.2 38.0%  
P/CF ratio (eoy) x7.228.1 25.8%  
Price / Book Value ratio x1.410.7 13.1%  
Dividend payout %9.417.7 53.3%   
Avg Mkt Cap Rs m20,306125,299 16.2%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3552,570 208.4%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96117,275 92.4%  
Other income Rs m265166 159.6%   
Total revenues Rs m16,22617,442 93.0%   
Gross profit Rs m4,1035,807 70.7%  
Depreciation Rs m1,091451 242.0%   
Interest Rs m94449 1,931.3%   
Profit before tax Rs m2,3345,474 42.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,460 42.7%   
Profit after tax Rs m1,7114,014 42.6%  
Gross profit margin %25.733.6 76.5%  
Effective tax rate %26.726.7 100.2%   
Net profit margin %10.723.2 46.1%  
BALANCE SHEET DATA
Current assets Rs m11,0187,639 144.2%   
Current liabilities Rs m9,5172,715 350.6%   
Net working cap to sales %9.428.5 33.0%  
Current ratio x1.22.8 41.1%  
Inventory Days Days11043 255.6%  
Debtors Days Days3579 44.3%  
Net fixed assets Rs m16,3046,914 235.8%   
Share capital Rs m161177 91.2%   
"Free" reserves Rs m12,90711,442 112.8%   
Net worth Rs m14,51611,721 123.8%   
Long term debt Rs m4,189149 2,817.4%   
Total assets Rs m29,80514,814 201.2%  
Interest coverage x3.5112.9 3.1%   
Debt to equity ratio x0.30 2,274.9%  
Sales to assets ratio x0.51.2 45.9%   
Return on assets %8.927.4 32.5%  
Return on equity %11.834.2 34.4%  
Return on capital %17.546.5 37.7%  
Exports to sales %24.855.1 44.9%   
Imports to sales %3.76.0 62.2%   
Exports (fob) Rs m3,9569,527 41.5%   
Imports (cif) Rs m5961,038 57.5%   
Fx inflow Rs m4,95210,422 47.5%   
Fx outflow Rs m6971,678 41.5%   
Net fx Rs m4,2558,744 48.7%   
CASH FLOW
From Operations Rs m2,7863,264 85.4%  
From Investments Rs m-1,529-2,093 73.1%  
From Financial Activity Rs m-941-1,186 79.4%  
Net Cashflow Rs m316-15 -2,137.8%  

Share Holding

Indian Promoters % 61.4 73.8 83.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 1.6 238.7%  
FIIs % 12.7 7.6 167.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.0 130.0%  
Shareholders   46,261 20,968 220.6%  
Pledged promoter(s) holding % 35.8 4.4 814.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Infosys Woes, Insurance IPOs and Top Stocks in Action(Pre-Open)

On Monday, the share markets in India slumped in the final hours of trade and finished the day in red.The BSE Sensex closed lower by 266 points to end at 31,259.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS